Thermo Fisher Scientific Envafolimab Humanized Recombinant Human Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Human

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Human CD274/PD-L1/B7-H1

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

2.8 mg/mL

Purification

Protein A/G

Storage buffer

PBS, pH 7.4

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2911402

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Envafolimab (KN035) is the world`s first new fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc. Compared with the PD-1/PD-L1 antibodies currently on the market and under development, it has a distinct advantage . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and fast tumor penetration, which can improve the compliance of tumor patients and improve the quality of life of patients, which is in line with the future trend of long-term management of tumors as chronic diseases.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.